ClinicalTrials.gg
TerminatedNCT01079949Updated Feb 27, 2014Results posted

A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age

A Phase 2 interventional study of r-hLH + r-hFSH and r-hFSH in Infertility and Ovulation Induction, sponsored by Merck KGaA, Darmstadt, Germany. Terminated at 1 site in Spain. Open to female participants aged 35 Years to 42 Years. Per ClinicalTrials.gov, last updated 2014-02-27.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment

Why this study was terminated
Trial was terminated due to low recruitment rate

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
35 Years to 42 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing lutropin alfa in Infertility — 1 open to participants now, 1 under way, 1 of them phase 3. lutropin alfa · Infertility.

Enrollment
5th of 11
93 · median 90
Started
2007
with 1 other
Phase 2
3 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
3 of 11
Merck KGaA, Darmstadt, Germany

Among the 11 studies testing lutropin alfa in Infertility, this one is the 5th largest by enrollment, is one of 2 that started in 2007, is one of 3 in phase 2, and was the 4th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 11 studies testing lutropin alfa in Infertility is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lutropin alfa

lutropin alfa: first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 35 Years to 42 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing lutropin alfa in Infertility, or all of them as a file.
02

Study summary

Ovarian reserve is related to chronological age; 35 years of age is the accepted threshold for significant decline in assisted reproductive technologies (ART) success with scarce follicular recruitment and poor oocyte retrieval. New therapeutic schemes are sought to improve follicular response in ovarian ageing because of the increasing number of infertile women aged older than 35 years who are trying to get pregnant. The advent of gonadotropin releasing hormone analogue antagonist (GnRHant) offers new perspectives to address the issues related to advanced reproductive age since it prevents premature luteinizing hormone (LH) surges while not causing suppression in the early follicular phase. Gonadotropin releasing hormone analogue antagonists are administered in the latter stage of the ovarian stimulation to prevent LH surge by competitive blockade of gonadotropin releasing hormone (GnRH) receptors, thus producing a marked decrease in LH levels just when the interplay between follicle stimulating hormone (FSH) and LH becomes important to complete follicular development and oocyte competence. Some studies in the past have shown the potential of recombinant human LH (r-hLH) supplementation in women of advanced reproductive age to improve oocyte quality, but these studies are of small size and did not provide data on the physiological mechanism behind the benefit obtained.

This randomized, comparative, parallel controlled Phase II study will be conducted in infertile female subjects aged 35-42 years undergoing in-vitro fertilization (IVF)/intra cytoplasmic sperm injection (ICSI), to investigate whether the addition of r-hLH (when the lead follicle is greater than [>] 14 millimeter [mm] in size), to the standard protocol with recombinant human FSH (r-hFSH) under GnRHant, improves the number and quality of oocytes retrieved, implantation rate, and pregnancy rate, while assessing the hormonal milieu in the ovarian follicular fluid. Comparison will be performed against ovarian stimulation without addition of r-hLH, that is (i.e.) with r-hFSH under GnRHant alone.

Read the detailed description

Preclinical pharmacology studies have demonstrated that r-hLH has a LH/human chorionic gonadotropin (hCG) receptor affinity similar to pituitary human luteinizing hormone (p-hLH), and is biologically active in-vitro in stimulating steroidogenesis and in promoting oocyte germinal vesicle breakdown. Several clinical studies have investigated the usefulness of r-hLH supplementation in normal ovulatory women undergoing ART and in almost all of them sub-populations of subjects have been identified who will benefit, when r-hLH is added to FSH.

OBJECTIVES

Primary objectives:

  • To determine the efficacy of adding r-hLH at mid-follicular phase compared to not adding r-hLH, in women of 35-42 years of age included in a COS with r-hFSH under treatment with a GnRHant for IVF/ICSI, assessed by the number and quality of the oocyte
  • To determine the safety of using r-hLH combined with r-hFSH in a protocol with a GnRHant, including incidence of ovarian hyperstimulation syndrome (OHSS) and adverse events (AEs) as well as local tolerability

Secondary objectives:

  • To complete the verification of efficacy with additional assessments such as follicular growth, oocyte fertilization, embryo quality and pregnancy rates
  • To investigate the underlying mechanism of possible improvement in oocyte quality by means of determining hormone levels (LH, FSH, T, E2, and hCG) levels in follicular fluid

Tertiary objectives:

  • This is a phase-II study that did not aim to carry out assessment of pharmacoeconomics or quality of life

All subjects will undergo treatment with r-hFSH at a daily dose of 300-450 IU by subcutaneous route starting on the stimulation Day 1 (S1) until r-hCG administration. Upon detection of a lead follicle > 14 mm in diameter, GnRHant 0.25 milligram (mg)/day subcutaneous administration will be initiated and continued up to r-hCG administration day. Subjects will be then randomly allocated (at any time between S1 and GnRHant initiation day) either to additional treatment with r-hLH at a daily fixed dose of 150 IU or continue treatment with r-hFSH alone. Gonadotropin releasing hormone antagonist and combined treatment with r-hLH plus (+) r-hFSH or r-hFSH alone will be administered until at least one follicle > 18 mm in diameter and two additional follicles > 16 mm in diameter are present and E2 levels are commensurate with the number and size of follicles present. A single injection of 250-500 microgram of r-hCG, will be given to induce final follicular maturation within 36 hours of the last r-hLH and/or r-hFSH injections and on the same day of the last GnRHant morning administration. Oocytes will be retrieved 34-38 hours after r-hCG administration, assessed, and fertilized in-vitro by ICSI. Not more than 3 embryos will be replaced on day 2 or 3 after OPU. The luteal phase will be supported by a daily vaginal administration of natural progesterone, starting after OPU and continuing either up to menstruation or the pregnancy test or, if the subject is pregnant, for at least 30 days after laboratory evidence of pregnancy. Each subject will be followed-up and the treatment outcome (pregnancy or menstruation) will be recorded.

For all subjects who received r-hCG and do not menstruate, a blood sample will be collected for local determination of serum beta-hCG level between post-hCG days 15-20. If positive (beta-hCG > 10 International Unit/liter [IU/L]), it should be confirmed by performing a second test within one week later. An ultrasound scan (US) will be performed at post-hCG days 35-42 on all subjects who will become pregnant provided that no miscarriage has occurred. The number of fetal sacs and fetal heart activity will be recorded. Active follow-up of all pregnancies will be performed, including those subjects withdrawn from the study.

03

Conditions studied

  • Infertility
  • Ovulation Induction

Browse trials for

Keywords

  • Infertility
  • Ovulation induction
  • Luveris
  • Lutropin alfa
  • Controlled ovarian stimulation
  • Reproductive technologies, Assisted
04

Who can participate

Ages eligible
35 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Premenopausal woman, aged 35 to 42 years wanting to become pregnant
  • Subjects with FSH baseline plasma levels less than or equal to 10 IU/L (Day 2-5 of the cycle) and with LH and E2 levels within the normal limits of the local laboratory
  • Subjects having regular spontaneous menstrual cycle lasting 25-35 days
  • Subjects with infertility that is susceptible to treatment with IVF/ICSI
  • Subjects to be included in a COS protocol with r-hFSH and GnRHant
  • Subjects with partner's sperm suitable for IVF/ICSI according to local laboratory, unless sperm donor is to be used
  • Subjects with both ovaries
  • Subjects with uterine cavity capable of sustaining the implantation of embryo or carrying a pregnancy
  • Subjects with normal pap smear (papanicolaou) 6 months prior to be included in the study (signature of )
  • Subjects with (BMI) less than (\<) 30 at the beginning of ovarian stimulation
  • Subjects with confirmed absence of pregnancy with the beta-hCG test (urine or blood) before starting the administration of r-hFSH
  • Subjects willing to adjust to the protocol for the entire duration of the study
  • Subjects who have given informed consent prior to any study-related procedure that is not part of normal medical care

Exclusion criteria

Exclusion Criteria:

  • Subjects or her partner with known positivity for (HIV) or Hepatitis-B /Hepatitis-C virus (/)
  • Subjects with any systemic illnesses of clinical significance, hypothalamus and pituitary tumors; cancer of ovaries, uterus or breast; hormonal anomalies and/or medical, biochemical, hematological illnesses that, according to the investigator, could interfere with the treatment with gonadotropins
  • Subjects with more than 2 previous ART cycles
  • Subjects who have cancelled two previous ART cycles
  • Subjects with frozen embryos from previous ART cycles
  • Subjects with non-specific gynecological bleeding
  • Subjects with ovaries that are polycystic, increased in size or with cysts of unknown etiology
  • Subjects with any for becoming pregnant and/or carrying pregnancy to term
  • Subjects with known allergy to gonadotropin preparations or any of the
  • Subjects with drug dependence or history of drug or alcohol abuse in the previous 5 years
  • Subjects who have previously entered into this study or simultaneous participation in another clinical drug trial with drugs
  • Subjects who are unwilling to or not being able to adjust to the study protocol
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    r-hLH + r-hFSH

    Drug: r-hLH + r-hFSH · Drug: Recombinant Human Choriogonadotropin (r-hCG) · Drug: GnRH antagonist

  • Active comparator
    r-hFSH

    Drug: r-hFSH · Drug: Recombinant Human Choriogonadotropin (r-hCG) · Drug: GnRH antagonist

Interventions

  • Drugr-hLH + r-hFSH

    Drug page: Lutropin alfa

    Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from stimulation Day 1(S1) at a starting dose of 300-450 International Unit (IU) and then dose adjusted depending on the ovarian response till recombinant human choriogonadotropin (r-hCG) administration day. Recombinant human luteinizing hormone (r-hLH, Luveris®, Lutropin alfa) injection will be administered subcutaneously once daily at a constant dose of 150 IU with flexible start, depending on the follicular growth (when the lead follicle is greater than 14 mm in size), along with r-hFSH treatment as a separate injection till r-hCG administration day.

    Also known as: Luveris®, Lutropin alfa

  • Drugr-hFSH

    Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from S1 at a starting dose of 300-450 IU and then dose adjusted depending on the ovarian response till r-hCG administration day.

  • The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.

    Also known as: Ovitrelle®

  • The GnRH antagonist will be administered at a starting at a dose of 0.25 milligram (mg) subcutaneously daily in the morning when the ultrasound discovers a follicle of greater than or equal to (\>=) 14 mm, and maintained until at least one follicle of \>=18 mm and two additional follicles of \>=16 mm with appropriate plasma estradiol levels for the number and size of the existing follicles.

    Also known as: Cetrotide®

06

What researchers measure

Primary outcomes

  1. Number of Oocytes Retrieved

    Number of oocytes retrieved per reporting group on the day of ovum pick-up (OPU) (34-38 hours post r-hCG day) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization (IVF) in order to remove oocytes from the ovary of the female participant, enabling fertilization outside the body.

    Time frame: Ovum pick-up (OPU) day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])

  2. Number of Mature Oocytes Retrieved

    Number of mature oocytes retrieved per reporting group on the day of OPU (34-38 hours post r-hCG day) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body. The nuclear maturity is assessed based on the presence of a germinal vesicle (GV) or whether oocytes were in metaphase I (Meta-I) or II (Meta-II) stage or atretic.

    Time frame: OPU day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])

  3. Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)

    Ovarian Hyper Stimulation Syndrome (OHSS) is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.

    Time frame: S1 to 1 month ± 1 week post r-hCG day (end of stimulation cycle [approximately 9 days])

  4. Number of Cycles Cancelled Due to Risk of Ovarian Hyper Stimulation Syndrome (OHSS)

    Ovarian Hyper Stimulation Syndrome (OHSS) is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.

    Time frame: S1 to 1 month ± 1 week post r-hCG day (end of stimulation cycle [approximately 9 days])

  5. Number of Participants With Adverse Events (AEs)

    An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered.

    Time frame: S1 to 1 month ± 1 week post r-hCG day (end of stimulation cycle [approximately 9 days])

Secondary outcomes

  1. Number of Follicles Greater Than or Equal to 14 Millimeter (mm) on Recombinant Human Choriogonadotropin (r-hCG) Day

    Time frame: r-hCG day (end of stimulation cycle [approximately 9 days])

  2. Endometrial Thickness on Recombinant Human Choriogonadotropin (r-hCG) Day

    Endometrial thickness measurement was performed on the day of r-hCG administration.

    Time frame: r-hCG day (end of stimulation cycle [approximately 9 days])

  3. Number of Fertilized Oocytes (2 Pronuclei [PN])

    Oocytes were fertilized using Intra-cytoplasmic Sperm Injection (ICSI) technique which is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. The appearance of 2PN is the first sign of successful fertilization as observed during in vitro fertilization, and is usually observed after ICSI. The zygote is then termed 2PN.

    Time frame: OPU day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])

  4. Number of Fertilized Oocytes at Stage 2 Pronuclei (2PN) or Higher Than 2PN

    Oocytes were fertilized using ICSI technique which is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. The appearance of 2PN is the first sign of successful fertilization as observed during in vitro fertilization, and is usually observed after ICSI. The zygote is then termed 2PN. Fertilized oocytes at stage higher then 2PN are those oocytes which consist more than 2 pronuclei like oocyte having 3 pronuclei termed as 3PN, oocyte having 4 pronuclei termed as 4PN.

    Time frame: Day 35-42 post r-hCG day (end of stimulation cycle [approximately 9 days])

  5. Number and Quality of Embryos

    Embryos were classified into 5 different grades (1 to 5) based on their capacity of implantation. Grade 1 embryos were those with best capacity of implantation and Grade 5 embryos were those with worst capacity of implantation.

    Time frame: Day 2-3 post OPU (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])

  6. Implantation Rate

    Implantation rate was measured as the number of gestational sacs observed, divided by the number of embryos transferred multiplied by 100.

    Time frame: Day 35-42 post OPU (34-38 hours post r-hCG day {end of stimulation cycle [approximately 9 days]})

  7. Number of Participants With Clinical Pregnancies

    Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.

    Time frame: Day 35-42 post r-hCG day (end of stimulation cycle [approximately 9 days])

  8. Number of Participants in Whom Recombinant Human Chorionic Gonadotropin (r-hCG) Was Not Administered Due to Poor Response

    Poor response was defined as 3 or less follicles of greater than or equal to 12 mm developing following at least 7 days of study treatment.

    Time frame: r-hCG day (end of stimulation cycle [approximately 9 days])

  9. Number of Ovarian Stimulation Days

    Ovarian stimulation included from first r-hFSH injection (S1) until day on which r-hCG was administered (r-hCG day).

    Time frame: Day 1 of stimulation period (S1) up to r-hCG day (end of stimulation cycle [approximately 9 days])

  10. Total Dose of Recombinant Human Follicle Stimulating Hormone (r-hFSH)

    Time frame: Day 1 of stimulation period (S1) up to r-hCG day (end of stimulation cycle [approximately 9 days])

  11. Estradiol (E2) Levels on r-hCG Day

    Time frame: r-hCG day (end of stimulation cycle [approximately 9 days])

  12. Follicular Levels of Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH) and Human Chorionic Gonadotropin (hCG) at Ovum Pick up (OPU)

    Time frame: OPU day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])

  13. Follicular Levels of Estradiol (E2) at Ovum Pick up (OPU)

    Time frame: OPU day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])

  14. Follicular Levels of Testosterone (T) at Ovum Pick up (OPU)

    Time frame: OPU day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])

07

Results

Posted Feb 20, 2013

Participant flow

Participant flow — Overall Study
Milestoner-hFSH + r-hLHr-hFSH
Started4647
Completed3134
Not completed1513
Withdrew: Withdrawal before r-hcg administration23
Withdrew: Withdrawal between rhcg-ovum pickup(opu)48
Withdrew: Withdrawal between opu - embryo transfer82
Withdrew: Randomized but not treated10

Outcome measures

PrimaryNumber of Oocytes Retrieved

Number of oocytes retrieved per reporting group on the day of ovum pick-up (OPU) (34-38 hours post r-hCG day) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization (IVF) in order to remove oocytes from the ovary of the female participant, enabling fertilization outside the body.

Time frame:
Ovum pick-up (OPU) day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])
Reported as:
Mean · oocytes
Number of Oocytes Retrieved
oocytesr-hFSH + r-hLHr-hFSH
Number of Oocytes Retrieved10 ± 3.810 ± 5.2
Statistical analysis
  • r-hFSH + r-hLH vs r-hFSH · Wilcoxon two sample test · p = 0.5739
PrimaryNumber of Mature Oocytes Retrieved

Number of mature oocytes retrieved per reporting group on the day of OPU (34-38 hours post r-hCG day) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body. The nuclear maturity is assessed based on the presence of a germinal vesicle (GV) or whether oocytes were in metaphase I (Meta-I) or II (Meta-II) stage or atretic.

Time frame:
OPU day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])
Reported as:
Number · mature oocytes
Number of Mature Oocytes Retrieved
mature oocytesr-hFSH + r-hLHr-hFSH
Geminal vesicle (GV)6037
Meta-I4426
Meta-II275292
Atresic104
PrimaryNumber of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)

Ovarian Hyper Stimulation Syndrome (OHSS) is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.

Time frame:
S1 to 1 month ± 1 week post r-hCG day (end of stimulation cycle [approximately 9 days])
Reported as:
Number · participants
Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)
participantsr-hFSH + r-hLHr-hFSH
Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)00
PrimaryNumber of Cycles Cancelled Due to Risk of Ovarian Hyper Stimulation Syndrome (OHSS)

Ovarian Hyper Stimulation Syndrome (OHSS) is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.

Time frame:
S1 to 1 month ± 1 week post r-hCG day (end of stimulation cycle [approximately 9 days])
Reported as:
Number · cycles
Number of Cycles Cancelled Due to Risk of Ovarian Hyper Stimulation Syndrome (OHSS)
cyclesr-hFSH + r-hLHr-hFSH
Number of Cycles Cancelled Due to Risk of Ovarian Hyper Stimulation Syndrome (OHSS)00
PrimaryNumber of Participants With Adverse Events (AEs)

An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered.

Time frame:
S1 to 1 month ± 1 week post r-hCG day (end of stimulation cycle [approximately 9 days])
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsr-hFSH + r-hLHr-hFSH
Number of Participants With Adverse Events (AEs)30
SecondaryNumber of Follicles Greater Than or Equal to 14 Millimeter (mm) on Recombinant Human Choriogonadotropin (r-hCG) Day
Time frame:
r-hCG day (end of stimulation cycle [approximately 9 days])
Reported as:
Mean · follicles
Number of Follicles Greater Than or Equal to 14 Millimeter (mm) on Recombinant Human Choriogonadotropin (r-hCG) Day
folliclesr-hFSH + r-hLHr-hFSH
Number of Follicles Greater Than or Equal to 14 Millimeter (mm) on Recombinant Human Choriogonadotropin (r-hCG) Day8.6 ± 3.97.4 ± 3.9
Statistical analysis
  • r-hFSH + r-hLH vs r-hFSH · Wilcoxon two sample test · p = 0.1734
SecondaryEndometrial Thickness on Recombinant Human Choriogonadotropin (r-hCG) Day

Endometrial thickness measurement was performed on the day of r-hCG administration.

Time frame:
r-hCG day (end of stimulation cycle [approximately 9 days])
Reported as:
Mean · mm
Endometrial Thickness on Recombinant Human Choriogonadotropin (r-hCG) Day
mmr-hFSH + r-hLHr-hFSH
Endometrial Thickness on Recombinant Human Choriogonadotropin (r-hCG) Day9.5 ± 2.18.8 ± 2.2
Statistical analysis
  • r-hFSH + r-hLH vs r-hFSH · Wilcoxon two sample test · p = 0.0642
SecondaryNumber of Fertilized Oocytes (2 Pronuclei [PN])

Oocytes were fertilized using Intra-cytoplasmic Sperm Injection (ICSI) technique which is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. The appearance of 2PN is the first sign of successful fertilization as observed during in vitro fertilization, and is usually observed after ICSI. The zygote is then termed 2PN.

Time frame:
OPU day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])
Reported as:
Number · 2PN oocytes
Number of Fertilized Oocytes (2 Pronuclei [PN])
2PN oocytesr-hFSH + r-hLHr-hFSH
Number of Fertilized Oocytes (2 Pronuclei [PN])203203
SecondaryNumber of Fertilized Oocytes at Stage 2 Pronuclei (2PN) or Higher Than 2PN

Oocytes were fertilized using ICSI technique which is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. The appearance of 2PN is the first sign of successful fertilization as observed during in vitro fertilization, and is usually observed after ICSI. The zygote is then termed 2PN. Fertilized oocytes at stage higher then 2PN are those oocytes which consist more than 2 pronuclei like oocyte having 3 pronuclei termed as 3PN, oocyte having 4 pronuclei termed as 4PN.

Time frame:
Day 35-42 post r-hCG day (end of stimulation cycle [approximately 9 days])
Reported as:
Number · oocytes
Number of Fertilized Oocytes at Stage 2 Pronuclei (2PN) or Higher Than 2PN
oocytesr-hFSH + r-hLHr-hFSH
Number of Fertilized Oocytes at Stage 2 Pronuclei (2PN) or Higher Than 2PN210210
SecondaryNumber and Quality of Embryos

Embryos were classified into 5 different grades (1 to 5) based on their capacity of implantation. Grade 1 embryos were those with best capacity of implantation and Grade 5 embryos were those with worst capacity of implantation.

Time frame:
Day 2-3 post OPU (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])
Reported as:
Number · embryos
Number and Quality of Embryos
embryosr-hFSH + r-hLHr-hFSH
12239
24635
35649
41813
56470
SecondaryImplantation Rate

Implantation rate was measured as the number of gestational sacs observed, divided by the number of embryos transferred multiplied by 100.

Time frame:
Day 35-42 post OPU (34-38 hours post r-hCG day {end of stimulation cycle [approximately 9 days]})
Reported as:
Mean · percent sacs per embryo
Implantation Rate
percent sacs per embryor-hFSH + r-hLHr-hFSH
Implantation Rate30 ± 3020 ± 30
Statistical analysis
  • r-hFSH + r-hLH vs r-hFSH · Wilcoxon two sample test · p = 0.4080
SecondaryNumber of Participants With Clinical Pregnancies

Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.

Time frame:
Day 35-42 post r-hCG day (end of stimulation cycle [approximately 9 days])
Reported as:
Number · participants
Number of Participants With Clinical Pregnancies
participantsr-hFSH + r-hLHr-hFSH
Number of Participants With Clinical Pregnancies1412
SecondaryNumber of Participants in Whom Recombinant Human Chorionic Gonadotropin (r-hCG) Was Not Administered Due to Poor Response

Poor response was defined as 3 or less follicles of greater than or equal to 12 mm developing following at least 7 days of study treatment.

Time frame:
r-hCG day (end of stimulation cycle [approximately 9 days])
Reported as:
Number · participants
Number of Participants in Whom Recombinant Human Chorionic Gonadotropin (r-hCG) Was Not Administered Due to Poor Response
participantsr-hFSH + r-hLHr-hFSH
Number of Participants in Whom Recombinant Human Chorionic Gonadotropin (r-hCG) Was Not Administered Due to Poor Response13
SecondaryNumber of Ovarian Stimulation Days

Ovarian stimulation included from first r-hFSH injection (S1) until day on which r-hCG was administered (r-hCG day).

Time frame:
Day 1 of stimulation period (S1) up to r-hCG day (end of stimulation cycle [approximately 9 days])
Reported as:
Mean · days
Number of Ovarian Stimulation Days
daysr-hFSH + r-hLHr-hFSH
Number of Ovarian Stimulation Days9.4 ± 1.38.8 ± 1.5
Statistical analysis
  • r-hFSH + r-hLH vs r-hFSH · Wilcoxon two sample test · p = 0.0648
SecondaryTotal Dose of Recombinant Human Follicle Stimulating Hormone (r-hFSH)
Time frame:
Day 1 of stimulation period (S1) up to r-hCG day (end of stimulation cycle [approximately 9 days])
Reported as:
Mean · IU
Total Dose of Recombinant Human Follicle Stimulating Hormone (r-hFSH)
IUr-hFSH + r-hLHr-hFSH
Total Dose of Recombinant Human Follicle Stimulating Hormone (r-hFSH)2916.1 ± 555.92861.7 ± 693.8
Statistical analysis
  • r-hFSH + r-hLH vs r-hFSH · ANOVA · p = 0.6799
SecondaryEstradiol (E2) Levels on r-hCG Day
Time frame:
r-hCG day (end of stimulation cycle [approximately 9 days])
Reported as:
Mean · picogram/milliter (pg/mL)
Estradiol (E2) Levels on r-hCG Day
picogram/milliter (pg/mL)r-hFSH + r-hLHr-hFSH
Estradiol (E2) Levels on r-hCG Day1813.9 ± 1063.61362.9 ± 774.1
Statistical analysis
  • r-hFSH + r-hLH vs r-hFSH · Wilcoxon two sample test · p = 0.0634
SecondaryFollicular Levels of Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH) and Human Chorionic Gonadotropin (hCG) at Ovum Pick up (OPU)
Time frame:
OPU day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])
Reported as:
Mean · milli international unit (mIU)/mL
Follicular Levels of Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH) and Human Chorionic Gonadotropin (hCG) at Ovum Pick up (OPU)
milli international unit (mIU)/mLr-hFSH + r-hLHr-hFSH
LH levels at OPU1.8 ± 0.92.0 ± 0.9
FSH levels at OPU8.3 ± 3.09.0 ± 3.7
hCG levels at OPU142.2 ± 72.7136.2 ± 65.8
SecondaryFollicular Levels of Estradiol (E2) at Ovum Pick up (OPU)
Time frame:
OPU day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])
Reported as:
Mean · pg/mL
Follicular Levels of Estradiol (E2) at Ovum Pick up (OPU)
pg/mLr-hFSH + r-hLHr-hFSH
Follicular Levels of Estradiol (E2) at Ovum Pick up (OPU)454508.0 ± 189835.8349605.3 ± 203895.8
Statistical analysis
  • r-hFSH + r-hLH vs r-hFSH · Wilcoxon two sample test · p = 0.0166
SecondaryFollicular Levels of Testosterone (T) at Ovum Pick up (OPU)
Time frame:
OPU day (34-38 hours post r-hCG day [end of stimulation cycle {approximately 9 days}])
Reported as:
Mean · nanogram/milliliter (ng/mL)
Follicular Levels of Testosterone (T) at Ovum Pick up (OPU)
nanogram/milliliter (ng/mL)r-hFSH + r-hLHr-hFSH
Follicular Levels of Testosterone (T) at Ovum Pick up (OPU)5.9 ± 1.56.0 ± 1.8
Statistical analysis
  • r-hFSH + r-hLH vs r-hFSH · ANOVA · p = 0.8812

Adverse events

Collected over S1 up to 1 month ± 1 week post r-hCG day (end of stimulation cycle [approximately 9 days]). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
r-hFSH + r-hLH—2/45 (4.4%)1/45 (2.2%)
r-hFSH—0/47 (0%)0/47 (0%)
Most frequent serious events
Most frequent serious events
Eventr-hFSH + r-hLHr-hFSH
Ectopic pregnancyPregnancy, puerperium and perinatal conditions2/450/47
Most frequent other events
Most frequent other events
Eventr-hFSH + r-hLHr-hFSH
VomitingGastrointestinal disorders1/450/47

Baseline characteristics

Age, Continuous
Age, Continuous(years)r-hFSH + r-hLHr-hFSHTotal
Mean36.6 ± 2.636.3 ± 3.036.4 ± 2.8
Sex: Female, Male
Sex: Female, Male(Participants)r-hFSH + r-hLHr-hFSHTotal
Female454792
Male000
08

Study locations

1 site
  • Instituto Marqués
    Barcelona, 08034, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2013, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2010
First posted
Mar 3, 2010
Start
Nov 2007
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results first posted
Feb 20, 2013
Last update
Feb 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01079949
Collaborators
Merck, S.L., Spain
Responsible party
Sponsor
First posted
Mar 3, 2010
Start date
Nov 2007
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Feb 20, 2013
Last update
Feb 27, 2014

Study contacts

Medical Responsible
study director · Merck, S.L., Spain

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutropin alfa

Start the discussion